These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from March 4 through March 10, 2021. Source: InsiderScore.com
Increases In Holdings
EcoR1 Capital lifted its stake in the clinical-stage immunology biotech to 7,151,624 shares, by buying 3,338,300 shares at prices that ranged from $18.70 to $25.48 from Feb. 23 through March 9.
EcoR1 characterized the fresh purchases as “an attractive investment opportunity.” EcoR1 is the largest shareholder of AnaptysBio with a 26.1% position in the company.
Decreases In Holdings
ValueAct Capital cut its position in the data-storage company by nearly a quarter, to 23,011,223 shares, selling a total of 7,135,450 Seagate shares from Jan. 4 through March 3. This included an apparent block-trade sale of 4,650,000 shares on March 3 at $72.75 each. The other sales occurred earlier, at prices ranging from $60.01 to $60.85 apiece.
ValueAct Capital cited no reason for the divestment, which reduces its stake to 9.7% of Seagate’s tradable stock.
Thomas H. Lee Partners slashed its interest in the contract clinical-trial-services firm by 31%, to 9,108,713 shares. The firm sold 3,718,778 shares at $74.18 each through an offering that closed on March 3. Thomas H. Lee sold an additional 277,176 shares directly to Syneos through a connected repurchase agreement, completed on the same day and at the same price. The firm’s reduced stake now stands at 8.8% of Snyeos’ outstanding stock.
Standard General lowered its interest in the television-station operator to 17,382,636 shares, or 7.9% of the outstanding stock. Standard General first sold 2,500,000 Tegna shares on March 8 at a per-share price of $19.01, then followed up by selling another 345,726 on March 9 at prices ranging from $19.04 to $19.09.
In January, Standard General presented four nominees to Tegna’s board to be elected at the coming annual shareholders meeting. On March 3, one of those representatives, media consultant Adonis Hoffman, notified Standard General that he would no longer be a nominee.
The Wall Street Journal reported that Hoffman withdrew due to a potential conflict of interest, citing an incident in 2014 when now-Tegna CEO David Lougee mistook Hoffman for a valet at an industry event. Hoffman was offended by the episode, and Lougee has said that he apologized to him at the time.
OrbiMed Advisors decreased its holding of the clinical-stage biopharmaceutical company to 6,186,307 shares. OrbiMed Advisors sold 1,220,000 SpringWorks shares on March 1 at $83.19 per share.
No reason was given for the sale, which leaves OrbiMed with a 12.6% interest in SpringWorks.